Compare Novo Nordisk A/S (NVO) vs Banco Santander SA (SAN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs Banco Santander SA — how do they compare? Novo Nordisk A/S trades at $46.27 (market cap $207.85B), while Banco Santander SA trades at $14.79 (market cap $211.63B). The key difference: Novo Nordisk A/S and Banco Santander SA are close in size by market cap, and Novo Nordisk A/S pays the higher dividend (3.81%). Which is the better fit depends on your goals.
| NVO | SAN | |
|---|---|---|
Market Cap | $207.85B | $211.63B |
Sector | Health | Financials |
52-Week High | $63.98 | $14.71 |
52-Week Low | $35.29 | $9.37 |
Enterprise Value | $222.55B | — |
Dividend Yield | 3.81% | 1.89% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NVO trades at $47.73, up 0.99% today, with a neutral technical signal and strong fundamentals, including a P/E of 11.62 and net income margin of 35.35%. Recent Q2 2026 earnings beat expectations, but the stock faces mixed sentiment due to competitive pressures and pricing headwinds in its GLP-1 portfolio.
The outlook is cautiously optimistic, supported by robust profitability and analyst buy ratings (57.9%), but risks include intense competition from Eli Lilly and margin compression. Upside potential hinges on execution against guidance, while downside risks stem from market share erosion.
Santander (SAN) trades at $14.80, up 0.75% today, with a bullish technical signal from moving averages. The stock shows strong fundamentals with a 26.25% net income margin and a P/E of 14.4. Recent news includes Federal Reserve approval for its $12 billion acquisition of Webster Bank, expected to close in August 2026, which may enhance its US market presence.
The outlook is positive, supported by analyst consensus (64% buy ratings) and record profitability. Key risks include volatile cash flows, with negative net cash flow in 2024, and integration challenges from the Webster deal. Revenue growth remains a catalyst, but investors should monitor execution risks and macroeconomic pressures on banking sectors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About Banco Santander SA
Santander's focus is on retail and commercial banking. Latin America is geographically the largest operation, with Brazil by far the largest. Its continental European business is still mainly Iberian. Santander's U.K. presence is the result of the acquisition of building society Abbey. In the U.S., Santander operates a vehicle finance business and a regional bank focused on the Northeastern states.
Read more on SAN →
